2018 News

Stay up to date on all that’s happening at Santen USA. For our global headquarters news, visit Santen Worldwide.

News

11.15.2018 Santen Expands Research and Development Leadership Team with Additions of Reza M. Haque, MD, PhD and Peter Sallstig, MD, MBA

11.07.2018 Santen Reports Consolidated Results for Q2 Fiscal 2018

10.22.2018 Santen Announces Initiation of Phase 3 Clinical Development Program (SPECTRUM) in the United States Evaluating Omidenepag Isopropyl (DE-117) for the Treatment of Glaucoma or Ocular Hypertension

09.25.2018 Santen Donates to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan

09.25.2018 Santen Announces Drug Discovery and Development Agreement with PeptiDream

09.21.2018 Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in Japan

08.01.2018 Santen Reports the 1st Quarter Fiscal 2018 Consolidated Performance

06.04.2018 Santen Announces Medium-Term Plan (MTP 2020)

05.09.2018 Santen Reports Consolidated Results for Fiscal 2017

02.12.2018 Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients with Refractory Wet Age-Related Macular Degeneration

Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved